Seeking Alpha

Amgen colorectal cancer drug gains expanded U.S. approval

  • Amgen (AMGN) says the FDA has approved its Vectibix drug as an initial treatment in patients with a type of advanced colorectal cancer who first undergo genetic screening.
  • AMGN says the drug was cleared as an initial treatment in conjunction with chemotherapy for patients whose tumors have a gene mutation that renders their cancer susceptible to the medicine.
  • The FDA agency also cleared Qiagen’s (QGEN) test that can show whether Vectibix will be effective in patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector